Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness
- PMID: 34550902
- DOI: 10.1212/WNL.0000000000012027
Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness
Comment on
-
Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.Neurology. 2021 Jun 1;96(22):e2673-e2684. doi: 10.1212/WNL.0000000000012022. Neurology. 2021. PMID: 34550903 Free PMC article.
Similar articles
-
Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials.Am J Geriatr Psychiatry. 2015 Dec;23(12):1234-1249. doi: 10.1016/j.jagp.2015.07.007. Epub 2015 Jul 21. Am J Geriatr Psychiatry. 2015. PMID: 26601726 Review.
-
Assessing cognition in Alzheimer disease research.Alzheimer Dis Assoc Disord. 1997;11 Suppl 6:45-9. Alzheimer Dis Assoc Disord. 1997. PMID: 9437447
-
[Heterogeneity of cognitive deficits in Alzheimer's and cognition therapy: research design ].Can J Aging. 2005 Fall;24(3):275-84. doi: 10.1353/cja.2005.0073. Can J Aging. 2005. PMID: 16421851 Review. French.
-
Comparison of multiple interventions for older adults with Alzheimer disease or mild cognitive impairment: A PRISMA-compliant network meta-analysis.Medicine (Baltimore). 2018 May;97(20):e10744. doi: 10.1097/MD.0000000000010744. Medicine (Baltimore). 2018. PMID: 29768349 Free PMC article.
-
Nonpharmacological treatment of Alzheimer disease.Can J Psychiatry. 2011 Oct;56(10):589-95. doi: 10.1177/070674371105601004. Can J Psychiatry. 2011. PMID: 22014691 Review.
Cited by
-
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease.Aging Cell. 2023 Aug;22(8):e13871. doi: 10.1111/acel.13871. Epub 2023 Jun 8. Aging Cell. 2023. PMID: 37291760 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical